ROCKET PHARMACEUTICALS, INC. 8K

Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million, materially extending its cash runway into Q2 2028.

On June 12, 2026, Rocket Pharmaceuticals, Inc. announced that it has closed the sale of its FDA-granted Rare Pediatric Disease Priority Review Voucher, which it received in March 2026 in connection with the approval of its gene therapy KRESLADI™ for severe leukocyte adhesion deficiency-I, generating $180 million in gross, non-dilutive proceeds and increasing its pro forma cash, cash equivalents and investments from $144.4 million as of March 31, 2026 to approximately $322.6 million, which the company expects will fund operations into the second quarter of 2028.

Filing Facts

CIK

1281895

Ticker

-

Form

8K

Source Type

sec

Accession

0001140361-26-024997

Alert Tier

7